In this good practice case study, HCV Action visits the hepatitis C service at HMP Kirkham in Lancashire. Natalie Robinson and Alexandra Robson from the healthcare team at HMP Kirkham emphasise the importance and effectiveness of their opt-out testing system, whereby everybody at the prison is offered and strongly encouraged to undergo screening for hepatitis C. Natalie and Alexandra stress the benefits of testing in enabling health promotion around the prevention of hepatitis C.
Resources
Medical professional
Around 216,000 people in the UK are living with hepatitis C so it is important that all medical professionals have access to the latest training, information and advice on hepatitis C management. Find here links to relevant materials for clinicians, nurses, GPs, prison healthcare staff and other medical professionals.
Showing 261 to 270 of 349 resources
-
HMP Kirkham: Treating hepatitis C in prison
North West May 2014 Case study Video -
EASL Recommendations on Treatment of Hepatitis C: 2014
These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decisionmaking process by describing the optimal management of patients with acute and chronic HCV infections. These guidelines apply to therapies that will be approved within less than 6 months at the time of their publication.UK Apr 2014 Reports & Research, Tools & Templates, Strategy & Planning PDF -
HMP Leeds: Treating hepatitis C in prison
In this good practice case study, Dr Iain Brew, GP at Leeds Community Services NHS Trust, talks to HCV Action about HMP Leeds' innovative hepatitis C treatment service. Dr Brew highlights prison as a highly effective setting in which to identify and treat people with hepatitis C.Yorkshire and the Humber 2014 Case study Video -
World Health Organisation (WHO) Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection
These are the first guidelines dealing with hepatitis C treatment produced by the World Health Organization (WHO) and complement existing guidance on the prevention of transmission of bloodborne viruses, including HCV. They are intended for policy-makers, government officials, and others working in low- and middle income countries who are developing programmes for the screening, care and treatment of persons with HCV infection.Rest of World Apr 2014 Tools & Templates, Strategy & Planning PDF -
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
These EASL Clinical Practice Guidelines (CPGs) are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the optimal management of patients with acute and chronic HCV infections. These guidelines apply to therapies that are approved at the time of their publication.UK, Rest of World 2014 Training, Reports & Research, Tools & Templates PDF -
Liver Disease: Today's Complacency, Tomorrow's Catastrophe. The All-Party Parliamentary Hepatology Group (APPHG) Inquiry into Improving Outcomes in Liver Disease
Out of disappointment at the persistent failure to develop a comprehensive approach to tackling liver disease, The All-Party Parliamentary Hepatology Group (APPHG) decided to conduct a comprehensive inquiry into the growing epidemic of liver disease. It invited evidence from Royal Colleges, clinicians, patients, charities, relevant industry figures, the NHS, Public Health England and the Government, in order to establish what needs to be done to improve outcomes for liver disease patients and save lives.UK 25 Mar 2014 Reports & Research PDF -
Hepatitis C Setting Standards in a Journey towards the Eradication of Infection and Disease as a Serious Health Issue in the EU
Initiatives which translate evidence and strategy into Hepatitis C Action are few and far between in the EU.UK, Rest of World 2014 Reports & Research, Strategy & Planning PDF -
New Treatments for Hepatitis C Virus: Strategies for Achieving Universal Access
This report summarises the current global treatment landscape for hepatitis C. The authors highlight 2014 as a 'turning-point in the history of the pandemic', but emphasise the detrimental impact of pharmaceutical company marketing strategies in making universal access to treatment practically unachievable. Suggestions for improving treatment access are put forth based on an examination of the lessons learnt from the fight against HIV/AIDS.UK, Rest of World 2014 Reports & Research PDF -
Can antiviral treatment for hepatitis C be safely and effectively delivered in primary care? A narrative systematic review of the evidence base
The burden of hepatitis C (HCV) treatment is growing, as is the political resolve to tackle the epidemic. Primary care will need to work more closely with secondary care to succeed in reducing the prevalence of chronic HCV. This paper, providing a narrative systematic review of six databases, aims to identify research relating to the provision of antiviral treatment for HCV in primary care.UK Dec 2013 Reports & Research PDF -
Charles Gore: A Call to HCV Action
A video call to action from Charles Gore, Executive Director of the Medicines Patent Pool, and ex-CEO of The Hepatitis C Trust, President of the World Hepatitis Alliance and HCV Action steering committee member.
UK, Rest of World 19 Nov 2013 Case study, Other Video